Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Neoplasms × Bevacizumab × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 30 Carcinoma, Hepatocellular 16 Ovarian Neoplasms 15 Neoplasms 15 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Brain Neoplasms 6 Neoplasm Metastasis 5 Liver Neoplasms 5 Breast Neoplasms 5 Glioma 4 Glioblastoma 4 Colonic Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neoplasms, Nerve Tissue 3 Lung Neoplasms 3 Gastrointestinal Neoplasms 3 Digestive System Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Biliary Tract Neoplasms 3 Peritoneal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Neoplasms by Site 2 Melanoma 2 Carcinoma, Renal Cell 2

Interventions

Capecitabine 8 Fluorouracil 7 Oxaliplatin 6 Nivolumab 6 Radiotherapy, Intensity-Modulated 4 Radiotherapy 4 Magnetic Resonance Spectroscopy 4 Leucovorin 4 Specimen Handling 3 Cetuximab 3 encorafenib 2 dehydroftorafur 2 X-Rays 2 Trastuzumab 2 Sigmoidoscopy 2 Radiation 2 Folfox protocol 2 Control Groups 2 Biopsy 2 zanidatamab 1 ulixertinib 1 trifluridine tipiracil drug combination 1 trastuzumab biosimilar HLX02 1 trametinib 1 sintilimab 1 sapanisertib 1 s-formylglutathione hydrolase 1 ropidoxuridine 1 relatlimab 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06997497 2026-04-13

KANDLELIT-012

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡